One injection in place of thirty tablets
According to Reuters, Teva leads the development and commercialisation of Weltruza, while the extended-release technology belongs to Medincell. The drug is injected under the skin once a month at three dose levels, 318 mg, 425 mg and 531 mg, corresponding to daily oral doses of 10 mg, 15 mg and 20 mg, according to Psychiatric Times.
For patients, the difference lies in the rhythm of life. Instead of remembering a pill every day, which is very hard when the illness itself disturbs thinking and motivation, they need only one appointment a month. For families and doctors, it is also a way of knowing for certain that the medicine has been taken.
The data behind the decision
The FDA's decision rests on a phase 3 trial called SOLARIS, conducted in several countries in adults aged 18 to 64. In the first eight weeks, 675 patients were randomly assigned to one of three dose groups or to placebo; 48 weeks of long-term follow-up came next. The main published points are:
- The drug improved symptom scores on the PANSS scale, reduced the severity of illness and improved social functioning compared with placebo, according to Teva.
- No case of post-injection delirium and sedation syndrome was recorded across 3,971 injections.











